An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
19
01
2022
accepted:
13
04
2022
pubmed:
2
5
2022
medline:
23
8
2022
entrez:
1
5
2022
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is associated with an increased risk for viral infections including those caused by herpes simplex virus and varicella zoster virus. This study examined treatment-emergent (TE) herpes simplex infection including eczema herpeticum (EH), and herpes zoster (HZ), in adult patients with AD receiving ≥1 dose of baricitinib (BARI), an oral selective inhibitor of Janus kinase 1/2. We evaluated data from six double-blinded, randomized, placebo-controlled (PC) trials and two long-term extension studies, within three analysis sets: PC, 2-4-mg BARI extended and All-BARI-AD. Frequency, incidence rate (IR)/100 person-years (PYs) and clinical characteristics of TE-herpes simplex, EH and HZ were reported. In the All-BARI-AD dataset (n = 2531; 2247 PYs), herpes simplex was reported in 8.9% of patients (n = 224; IR = 10.3). Most herpes simplex events were rated as mild or moderate (93.3%), rarely led to permanent discontinuation (2.2%) and presented mostly as oral/perioral herpes simplex (51.3%). TE-EH occurred at a low frequency (All-BARI-AD 1.7% n = 43; IR = 2.0) and were reported in 0.5%, 0.2% and 1.4% of patients receiving placebo, 2-mg or 4-mg BARI respectively. In the All-BARI-AD dataset, most events were investigator-rated as mild/moderate (79.1%), affected ≤2% of the body surface area (74.2%) and occurred as single events (88.4%). Serious TE-EH (n = 11) occurred exclusively in patients with poor disease control (vIGA-AD™ score ≥3) at infection onset. TE-HZ was reported in 2.1% of BARI patients (n = 53; IR = 2.3), without a dose relationship during the PC period (IR = 2.7 and IR = 0.0) or the extended dataset (IR = 3.7 and IR = 1.7) for 2- or 4-mg BARI respectively. TE-herpes simplex was common, while occurrence of EH was uncommon. Most events of EH were localized with involvement of a small BSA and were linked to poor disease control. Events of HZ were rare in the PC dataset and without a dose dependent increase in frequency.
Sections du résumé
BACKGROUND
BACKGROUND
Atopic dermatitis (AD) is associated with an increased risk for viral infections including those caused by herpes simplex virus and varicella zoster virus.
OBJECTIVES
OBJECTIVE
This study examined treatment-emergent (TE) herpes simplex infection including eczema herpeticum (EH), and herpes zoster (HZ), in adult patients with AD receiving ≥1 dose of baricitinib (BARI), an oral selective inhibitor of Janus kinase 1/2.
METHODS
METHODS
We evaluated data from six double-blinded, randomized, placebo-controlled (PC) trials and two long-term extension studies, within three analysis sets: PC, 2-4-mg BARI extended and All-BARI-AD. Frequency, incidence rate (IR)/100 person-years (PYs) and clinical characteristics of TE-herpes simplex, EH and HZ were reported.
RESULTS
RESULTS
In the All-BARI-AD dataset (n = 2531; 2247 PYs), herpes simplex was reported in 8.9% of patients (n = 224; IR = 10.3). Most herpes simplex events were rated as mild or moderate (93.3%), rarely led to permanent discontinuation (2.2%) and presented mostly as oral/perioral herpes simplex (51.3%). TE-EH occurred at a low frequency (All-BARI-AD 1.7% n = 43; IR = 2.0) and were reported in 0.5%, 0.2% and 1.4% of patients receiving placebo, 2-mg or 4-mg BARI respectively. In the All-BARI-AD dataset, most events were investigator-rated as mild/moderate (79.1%), affected ≤2% of the body surface area (74.2%) and occurred as single events (88.4%). Serious TE-EH (n = 11) occurred exclusively in patients with poor disease control (vIGA-AD™ score ≥3) at infection onset. TE-HZ was reported in 2.1% of BARI patients (n = 53; IR = 2.3), without a dose relationship during the PC period (IR = 2.7 and IR = 0.0) or the extended dataset (IR = 3.7 and IR = 1.7) for 2- or 4-mg BARI respectively.
CONCLUSIONS
CONCLUSIONS
TE-herpes simplex was common, while occurrence of EH was uncommon. Most events of EH were localized with involvement of a small BSA and were linked to poor disease control. Events of HZ were rare in the PC dataset and without a dose dependent increase in frequency.
Substances chimiques
Azetidines
0
Purines
0
Pyrazoles
0
Sulfonamides
0
baricitinib
ISP4442I3Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1486-1496Subventions
Organisme : Eli Lilly and Company
Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Chovatiya R, Silverberg JI. Association of herpes zoster and chronic inflammatory skin disease in US inpatients. J Am Acad Dermatol 2020; 85: 1437-1445.
Damour A, Garcia M, Seneschal J, Lévêque N, Bodet C. Eczema Herpeticum: clinical and pathophysiological aspects. Clin Rev Allergy Immunol 2020; 59: 1-18.
Paller A, Jaworski JC, Simpson EL et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol 2018; 19: 821-838.
Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections. Dermatitis 2020; 31: 157-164.
Leung DYM, Gao PS, Grigoryev DN et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response. J Allergy Clin Immunol 2011; 127: 965-973.
Gao L, Bin L, Rafaels NM et al. Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. J Allergy Clin Immunol 2015; 136: 1591-1600.
Simpson EL, Lacour JP, Spelman L et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.
Taylor PC, Takeuchi T, Burmester GR et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 2022; 81:335-343.
Bieber T, Thyssen JP, Reich K et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatology Venereol 2020; 35: 476-485.
Leung DYM, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014; 134: 769-779.
Seegräber M, Worm M, Werfel T et al. Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatology Venereol 2020; 34: 1074-1079.
Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49: 198-205.
Beck LA, Boguniewicz M, Hata T et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol 2009; 124: 260-269.
Wollenberg A, Christen-Zäch S, Taieb A et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.
Eichenfield LF, Bieber T, Beck LA et al. Infections in Dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol 2019; 20: 443-456.
Callewaert C, Nakatsuji T, Knight R et al. IL-4Rα blockade by Dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol 2020; 140: 191-202.e7.
Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2018; 78: 62-69.e1.
Winthrop KL, Curtis JR, Lindsey S et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 2017; 69: 1960-1968.
Wan J, Shin DB, Syed MN et al. Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study. Br J Dermatol. 2021; 186: 664-672.
Wollenberg A, Wagner M, Günther S et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 35: 452-456.
Simpson EL, Silverberg JI, Nosbaum A et al. Integrated safety analysis of Abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol 2021; 22: 693-707.
Kwon HJ, Bang DW, Kim EN et al. Asthma as a risk factor for zoster in adults: a population-based case-control study. J Allergy Clin Immunol 2016; 137: 1406-1412.
Baricitinib - Summary of product Characteristics. URL https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf. Accessed 16 Jul 2021.
Winthrop KL, Harigai M, Genovese MC et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis 2020; 79: 1290-1297.